Lyme disease

A new Lyme disease vaccine is about to enter its final phase of human trialling. If all goes well it could be available by 2025, making it the first vaccine for Lyme disease to reach the market in nearly a quarter of a century.

By studying the eating habits of the bacterium that causes Lyme disease, a team of scientists has pinpointed a new mechanism that could be used for early diagnosis of the condition, and potentially prevent its worst effects.

We've seen exciting progress made in genetically modifying mosquitos to fight malaria, and now scientists have used CRISPR technology to edit the genes of ticks for the first time, a significant breakthrough in the battle against Lyme disease.

A new study is reporting the development of a novel mRNA-based vaccine designed to help resist tick bites. Preclinical tests in guinea pigs indicate the vaccine aids the immune system in recognizing tick bites before they can transmit any disease.

A new study has revealed that an already-approved antibiotic can completely eliminate the underlying bacteria that causes Lyme disease in mice, offering new hope of a more comprehensive therapy for humans.